RecruitingNot Applicable

Impact of Endo-vac Therapy for Esophago-jejunal Anastomotic Leak

Ukraine100 participantsStarted 2025-12-01

Plain-language summary

The goal of this observational study is to assess the impact of endoscopic vacuum therapy in patients who underwent total gastrectomy due to gastric cancer and developed esophago-jejunal anastomotic leakage. The main outcomes to be investigated are the following: Primary endpoint: mortality rate Secondary endpoints: morbidity rate, time from AL diagnosis to discharge, patients satisfactory rate.

Who can participate

Age range

18 Years – 90 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients who developed esophago-jejunal anastomotic leak less than 50% of circumference of anastomosis * patients who developed esophago-jejunal anastomotic leak and remained stable at the moment of diagnosis with no indications for diversion surgery Exclusion Criteria: * unstable patients who developed esophago-jejunal anastomotic leak * patients who developed esophago-jejunal anastomotic leak more than 50% or anastomotic circumference * patients who rejected endoscopic vacuum therapy

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Mortality rate

Timeframe: 90 days after last endo-vac placement

Trial details

NCT IDNCT07295236

SponsorUkrainian Society of Clinical Oncology

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2030-12-01

Contact for this trial

Oleksii Dobrzhanskyi, MD

+380638760185 alekseydobrzhanskiy@gmail.com

View on ClinicalTrials.gov More Esophagojejunal Anastomotic Leak trials